Physician profile
James D Rutter
NPI 1649258369
$644.48
in general payments reported to CMS, 2019-2025
19 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $21.01 · 2021: $22.26 · 2022: $47.21 · 2023: $12.94 · 2024: $258 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $82.70 | 2022-2025 | Qelbree |
| Amgen INC. | $77.34 | 2019-2025 | Prolia, Evenity, Otezla |
| Corium, LLC | $76.29 | 2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $42.59 | 2019 | |
| Exact Sciences Corporation | $42.47 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $33.96 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $33.26 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $30.48 | 2024-2025 | |
| Lilly USA, LLC | $27.94 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.61 | 2019 | |
| Globus Medical, INC. | $25.31 | 2025 | Senza |
| Dexcom, INC. | $22.71 | 2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $22.26 | 2021 | |
| Mylan Specialty L.P. | $20.72 | 2019 | |
| Medtronic, INC. | $18.77 | 2025 | Interstim |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.03 | 2024 | Trelegy Ellipta |
| Pfizer INC. | $15.85 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $15.11 | 2019 | |
| Lundbeck LLC | $14.08 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.